The TICONC (Ticagrelor-Oncology) Study: Implications of P2Y₁₂ Inhibition for Metastasis and Cancer-Associated Thrombosis.

ABSTRACT:

Background

In cancer, platelets may facilitate metastatic spread by a number of mechanisms as well as contribute to thrombotic complications. Ticagrelor, a platelet antagonist- that blocks adenosine diphosphate activation of platelet P2Y₁₂ receptors, is widely used in the treatment of cardiovascular disease, but its efficacy in cancer remains unknown.

Objectives

This study sought to evaluate the effect of aspirin and ticagrelor monotherapy, as well as dual antiplatelet therapy, on platelet activation in cancer.

Methods

This study consisted of 2 phases: first, an in vitro study of human platelet-tumor cell interaction; and second, a randomized crossover clinical trial of 22 healthy donors and 16 patients with metastatic breast or colorectal cancer. Platelet

SUBMITTER: Wright JR 

PROVIDER: S-EPMC8352224 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature